myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Lea Monteran; Neta Erez

doi:10.1016/j.trecan.2022.11.001

myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Lea Monteran, Neta Erez

Tel Aviv University

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Trends in Cancer
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.trecan.2022.11.001
State	Published - Jan 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc.

Keywords

CAFs
LRRC15
PDAC
immune suppression
microenvironment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2022.11.001

Cite this

@article{0567e664acda4de09fdd1c89d5c17f42,

title = "myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy",

abstract = "New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.",

keywords = "CAFs, LRRC15, PDAC, immune suppression, microenvironment",

author = "Lea Monteran and Neta Erez",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = jan,

doi = "10.1016/j.trecan.2022.11.001",

language = "אנגלית",

volume = "9",

pages = "1--2",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - myCAFs are better than yours

T2 - targeting myofibroblasts potentiates immunotherapy

AU - Monteran, Lea

AU - Erez, Neta

PY - 2023/1

Y1 - 2023/1

N2 - New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

AB - New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

KW - CAFs

KW - LRRC15

KW - PDAC

KW - immune suppression

KW - microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85141515287&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2022.11.001

DO - 10.1016/j.trecan.2022.11.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???

C2 - 36371342

AN - SCOPUS:85141515287

SN - 2405-8033

VL - 9

SP - 1

EP - 2

JO - Trends in Cancer

JF - Trends in Cancer

IS - 1

ER -

myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this